 |
160 Products |  |
813 Diseases | | 160 Products |
|
1608 Trials |  |
78055 News |  |
| «12...882883884885886887888889890891892...903904» |
- | Ibrance (palbociclib) / Pfizer
New P1 trial: A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract (clinicaltrials.gov) - Apr 29, 2013
P1, N=24, Completed, Sponsor: Pfizer
- | Vectibix (panitumumab) / Amgen
New P2 trial: Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal (clinicaltrials.gov) - Apr 28, 2013
P2, N=65, Recruiting, Sponsor: Centre Hospitalier Universitaire Vaudois
- |||||| plerixafor / Generic mfg.
Enrollment open: Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5 (clinicaltrials.gov) - Apr 25, 2013
P3, N=100, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Trial completion: Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma (clinicaltrials.gov) - Apr 25, 2013
P2, N=98, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Parsabiv (etelcalcetide) / Amgen
Enrollment change: Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder (clinicaltrials.gov) - Apr 24, 2013
P2, N=37, Completed, Sponsor: KAI Pharmaceuticals
Active, not recruiting --> Completed N=30 --> 37
- Jakafi (ruxolitinib) / Incyte
Enrollment open, Combination therapy, Metastases: An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 24, 2013
P1, N=30, Recruiting, Sponsor: Incyte Corporation
N=30 --> 37 Not yet recruiting --> Recruiting
- | Parsabiv (etelcalcetide) / Amgen
Enrollment closed: Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism (clinicaltrials.gov) - Apr 24, 2013
P2, N=30, Active, not recruiting, Sponsor: KAI Pharmaceuticals
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- | Parsabiv (etelcalcetide) / Amgen
Trial completion: Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder (clinicaltrials.gov) - Apr 24, 2013
P2, N=37, Completed, Sponsor: KAI Pharmaceuticals
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- melphalan / Generic mfg., amifostine / Generic mfg.
Trial completion: Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect (clinicaltrials.gov) - Apr 24, 2013
P1/2, N=25, Completed, Sponsor: University of Kentucky
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial, Monotherapy, Metastases: Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (clinicaltrials.gov) - Apr 23, 2013
P1, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- vadacabtagene leraleucel (JCAR015) / BMS
New P1 trial: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 23, 2013
P1, N=18, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- AMG 151 / Amgen
Trial termination: Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects (clinicaltrials.gov) - Apr 18, 2013
P1, N=5, Terminated, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Terminated; Amgen determined no further need for this study.
- AMG 151 / Amgen
Enrollment change: Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects (clinicaltrials.gov) - Apr 18, 2013
P1, N=5, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Amgen determined no further need for this study. N=26 --> 5
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: SPARSE: A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis (clinicaltrials.gov) - Apr 15, 2013
P4, N=100, Completed, Sponsor: Pfizer
N=26 --> 5 N=80 --> 100
- ||| human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap
Enrollment change: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia (clinicaltrials.gov) - Apr 15, 2013
P1/2, N=82, Recruiting, Sponsor: Cellerant Therapeutics
N=80 --> 100 N=30 --> 82
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 15, 2013
P2, N=3, Completed, Sponsor: Fox Chase Cancer Center
N=30 --> 82 N=12 --> 3
- topotecan / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Metastases: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 15, 2013
P2, N=3, Completed, Sponsor: Fox Chase Cancer Center
N=12 --> 3 N=28 --> 3
- topotecan / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Metastases: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. (clinicaltrials.gov) - Apr 15, 2013
P2, N=3, Completed, Sponsor: Fox Chase Cancer Center
N=28 --> 3 N=25 --> 3
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial, Metastases: Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis (clinicaltrials.gov) - Apr 15, 2013
P1, N=24, Completed, Sponsor: Amgen
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: SPARSE: A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis (clinicaltrials.gov) - Apr 15, 2013
P4, N=100, Completed, Sponsor: Pfizer
N=25 --> 3 Recruiting --> Completed
- ||| Eprex (epoetin alfa) / J&J
Enrollment change: A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa (clinicaltrials.gov) - Apr 14, 2013
P4, N=124, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed N=750 --> 124
- ||||| oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2013
P1/2, N=128, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- ||| rilotumumab (AMG 102) / Amgen
Trial initiation date, Metastases: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer (clinicaltrials.gov) - Apr 11, 2013
P1/2, N=130, Completed, Sponsor: Amgen
N=750 --> 124 Initiation date: Aug 2008 --> Feb 2009
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed: Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC (clinicaltrials.gov) - Apr 11, 2013
P2, N=70, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Initiation date: Aug 2008 --> Feb 2009 Recruiting --> Active, not recruiting
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Combination therapy, Metastases: QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Apr 11, 2013
P2, N=155, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Combination therapy: QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Apr 11, 2013
P1/2, N=204, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| rilotumumab (AMG 102) / Amgen
Trial completion, Combination therapy: AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer (clinicaltrials.gov) - Apr 11, 2013
P1/2, N=162, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| rilotumumab (AMG 102) / Amgen
Trial completion, Metastases: A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Apr 11, 2013
P2, N=61, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Stivarga (regorafenib) / Bayer
Trial termination, IO biomarker: Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=4, Terminated, Sponsor: Dartmouth-Hitchcock Medical Center
Over nearly 2 years just 4 subjects were treated on study. The goal of 30 subjects was not attainable.
- Stivarga (regorafenib) / Bayer
Enrollment change, IO biomarker: Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=4, Terminated, Sponsor: Dartmouth-Hitchcock Medical Center
The goal of 30 subjects was not attainable. N=30 --> 4
- Trial termination, Metastases: Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer (clinicaltrials.gov) - Apr 9, 2013
P3, N=0, Terminated, Sponsor: Gynecologic Oncology Group
N=30 --> 4 Completed --> Terminated
- Trial termination: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Completed --> Terminated Completed --> Terminated
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy (clinicaltrials.gov) - Apr 9, 2013
P2, N=110, Recruiting, Sponsor: St. Jude Children's Research Hospital
Completed --> Terminated Not yet recruiting --> Recruiting
- ||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: EMBARK: Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes (clinicaltrials.gov) - Apr 9, 2013
P3, N=200, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial termination: Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma (clinicaltrials.gov) - Apr 7, 2013
P1, N=42, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated; Administratively complete.
- Rituxan (rituximab) / Roche
Trial termination: S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 7, 2013
P3, N=7, Terminated, Sponsor: Southwest Oncology Group
Completed --> Terminated; Administratively complete. Completed --> Terminated; lack of accrual
- ||||| Herceptin (trastuzumab) / Roche
New P2 trial: Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer (clinicaltrials.gov) - Apr 7, 2013
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Traficet-EN (vercirnon) / Amgen
New P1 trial: Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects (clinicaltrials.gov) - Apr 7, 2013
P1, N=21, Completed, Sponsor: GlaxoSmithKline
- | Stivarga (regorafenib) / Bayer
Trial completion: Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 7, 2013
P2, N=36, Completed, Sponsor: Bayer
Completed --> Terminated; lack of accrual Active, not recruiting --> Completed
- || prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment change: A Study of AMG 557 in Adults With Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 4, 2013
P1, N=58, Completed, Sponsor: Amgen
Active, not recruiting --> Completed N=48 --> 58
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
New P2 trial, Combination therapy, Metastases: Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension (EUDRACT) - Apr 4, 2013
P2, N=9, Ongoing, Sponsor: DAIICHI SANKYO DEVELOPMENT LTD.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) (clinicaltrials.gov) - Apr 4, 2013
P1, N=48, Completed, Sponsor: Amgen
- ||| prezalumab (AMG 557) / Amgen, AstraZeneca
Trial completion: A Study of AMG 557 in Adults With Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 4, 2013
P1, N=58, Completed, Sponsor: Amgen
N=48 --> 58 Recruiting --> Completed
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Apr 2, 2013
P3, N=18, Active, not recruiting, Sponsor: Amgen
- ||| brilanestrant (GDC-0810) / Roche
New P1 trial: A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Apr 2, 2013
P1, N=72, Recruiting, Sponsor: Seragon Pharmaceuticals, Inc.
- | Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Trial completion: Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) (clinicaltrials.gov) - Apr 2, 2013
P2, N=23, Completed, Sponsor: Hyperion Therapeutics, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| plerixafor / Generic mfg.
Trial initiation date: Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5 (clinicaltrials.gov) - Apr 1, 2013
P3, N=100, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Initiation date: Jan 2013 --> Apr 2013
- | Jakafi (ruxolitinib) / Incyte
New P1 trial, Combination therapy, Metastases: An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 31, 2013
P1, N=30, Recruiting, Sponsor: Incyte Corporation
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors (clinicaltrials.gov) - Mar 29, 2013
P3, N=20000, Recruiting, Sponsor: Center for International Blood and Marrow Transplant Research
Initiation date: Jan 2013 --> Apr 2013 N=15000 --> 20000
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 28, 2013
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=15000 --> 20000 Recruiting --> Active, not recruiting